Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

August 9, 2007

ERBITUX

This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Analysis By:
Taral Patel, MD, OncologistTaral Patel, MD
Oncologist, Mid Ohio Oncology Hematology Inc.
Implications: The comprehensive clinical program will supplement the significant body of clinical data existing for ERBITUX in colorectal and head and neck cancers by exploring the use of ERBITUX in additional tumor types including brain, breast, bladder, gastric, lung, pancreas and prostate

Analysis: Since erbitux fail to show significant improvement in colon cancer.
I am not sure erbitux will be effective in any orhter cancer except Head and neck

Other Analyses of the Same Source Article:
Erbitux is far from over in Colorectal Cancer
August 9, 2007, Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.
ERBITUX
August 9, 2007, Author: Taral Patel, MD, Oncologist, Mid Ohio Oncology Hematology Inc.
Wise Investment: Only time will tell!!!
August 3, 2007, Author: GLG Expert Contributor
Smart Move
August 2, 2007, Author: GLG Expert Contributor
Why not?
July 31, 2007, Author: GLG Expert Contributor

Report a Concern

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-11-21T13:45:47.600